A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks

1. Gathe, J.
2. Da Silva, B.A.
3. Cohen, D.E.
4. Loutfy, M.R.
5. Podzamczer, D.
6. Rubio, R.
7. Gibbs, S.
8. Marsh, T.
9. Naylor, C.
10. Fredrick, L.
11. Bernstein, B.